Skystar Bio Pharmaceutical Company Reports Consolidated Unaudited Earnings Results for the Second Quarter Ended July 30, 2012; Reiterates Fiscal 2012 Earnings Guidance
For the six months, the company reported revenue, net was $16,797,185 against $16,183,095 a year ago. Income from operations was $4,756,505 against $3,176,398 a year ago. Income before provision for income taxes was $4,655,362 against $4,198,377 a year ago. Net income was $3,603,620 against $3,439,222 a year ago. Diluted earnings per share was $0.48 against $0.48 per share a year ago. Net cash used in operating activities was $2,163,439 against $3,922,845 a year ago. Purchases of property, plant and equipment was $127,531 against $46,186 a year ago.
The company currently reiterate fiscal 2012 guidance to be in the range of $53 million to $57 million for the full year.